KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Gross Margin (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Gross Margin for 9 consecutive years, with 42.75% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 5533.0% to 42.75% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.25% through Dec 2025, up 3010.0% year-over-year, with the annual reading at 46.25% for FY2025, 4502.0% up from the prior year.
  • Gross Margin hit 42.75% in Q4 2025 for Bionano Genomics, down from 45.74% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 98.08% in Q4 2024 to a low of 139.07% in Q3 2024.
  • Historically, Gross Margin has averaged 25.0% across 5 years, with a median of 28.71% in 2023.
  • Biggest five-year swings in Gross Margin: tumbled -16858bps in 2024 and later soared 18482bps in 2025.
  • Year by year, Gross Margin stood at 3.79% in 2021, then skyrocketed by 479bps to 21.97% in 2022, then grew by 3bps to 22.74% in 2023, then surged by 331bps to 98.08% in 2024, then tumbled by -56bps to 42.75% in 2025.
  • Business Quant data shows Gross Margin for BNGO at 42.75% in Q4 2025, 45.74% in Q3 2025, and 51.64% in Q2 2025.